Mahamaya Lifesciences Ltd (MAHALIFE) — shareholding pattern, promoter holding, financials and share price
About Mahamaya Lifesciences Ltd (MAHALIFE)
Mahamaya Lifesciences Ltd operates in the Pesticides & Agrochemicals industry, within the Chemicals sector. It trades on the NSE as MAHALIFE and on the BSE under scrip code 544611. Its ISIN is INE0U9D01019.
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management. [1]
Listed peers in Pesticides & Agrochemicals: Best Agrolife Ltd, KN Agri Resources Ltd, Indogulf Cropsciences Ltd, Shivalik Rasayan Ltd, Sikko Industries Ltd, Shreeoswal Seeds & Chemicals Ltd.
Valuation & Returns
10 Jul 2026At ₹166 a share on 10 Jul 2026, Mahamaya Lifesciences Ltd (MAHALIFE) was valued at a price-to-earnings ratio of 23.51x against an industry P/E of 22.12x and a price-to-book of 3.19x on a book value of ₹52.09 per share. Solomo computes return on equity of 13.55% and return on capital employed of 15.05% from filed results.
- P/E
- 23.51x
- Industry P/E
- 22.12x
- P/B
- 3.19x
- EPS (TTM)
- ₹7.06
- Book value / share
- ₹52.09
- ROE
- 13.55%
- ROCE
- 15.05%
- ROA
- 5.32%
- Debt / equity
- 0.74x
- Dividend yield
- 0%
- EBITDA margin
- 10.42%
- 52-week range
- ₹111 – ₹205.05
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Mahamaya Lifesciences Ltd (MAHALIFE) reported revenue of ₹329 crore, net profit of ₹17 crore and earnings per share of ₹7.06. That compares with revenue of ₹264 crore and net profit of ₹13 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹166 crore and net profit ₹8 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 90 | 137 | 161 | 264 | 329 |
| Net profit (₹ cr) | 3 | 4 | 5 | 13 | 17 |
| EPS (₹) | 21.78 | 30.03 | 41.8 | 7.28 | 7.06 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 43.22% | 63.49% |
| Profit growth | 68.13% | 147.89% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 56.35% of Mahamaya Lifesciences Ltd (MAHALIFE), foreign institutional investors (FII) hold 4.77% and domestic institutional investors (DII) hold 2.52%. Market capitalisation was ₹389 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Mar 2026: PINK TIGER ALLIANCES LLP 10.35%, KEDIA SECURITIES PRIVATE LIMITED 4.53%, NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND 2.53%, MINERVA VENTURES FUND 2.28%, MULTIPLIER SHARE & STOCK ADVISORS PVT LTD 1.28%, GUJRANI FOODS PRIVATE LIMITED 1.08%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 56.35% | - | 4.77% | 2.52% | 43.65% |